Related references
Note: Only part of the references are listed.Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma
Ashley Wysong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients
Neha Singh et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
B. G. M. Hughes et al.
ANNALS OF ONCOLOGY (2021)
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Valerie Glutsch et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Alexander J. Stratigos et al.
LANCET ONCOLOGY (2021)
Immune checkpoint inhibitor administration during pregnancy: a case series
A. Andrikopoulou et al.
ESMO OPEN (2021)
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Paul Nghiem et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Renata Ferrarotto et al.
CLINICAL CANCER RESEARCH (2021)
Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: Analysis of a phase II, open-label clinical trial.
Alexander J. Stratigos et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Danny Rischin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
Sandra P. D'Angelo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629
Brett G. M. Hughes et al.
DERMATOLOGY AND THERAPY (2021)
Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter
Frederick C. Morgan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma
Michael T. Tetzlaff et al.
MODERN PATHOLOGY (2020)
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
Michael R. Migden et al.
LANCET ONCOLOGY (2020)
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature
Vivek Kumar et al.
ONCOLOGIST (2020)
Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
CANCERS (2020)
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.
Mark R. Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CA209-9JC: A phase II study of first-line nivolumab (NIVO) in patients (pts) with locally advanced or metastatic cutaneous squamous cell carcinoma.
Rodrigo Ramella Munhoz et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and safety of IO103 a novel anti PD-L1 vaccine in basal cell carcinoma.
Nicolai Grønne Jørgensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
PD-L1andLAG-3 expression in advanced cutaneous squamous cell carcinomas
Sam Wu et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2020)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M. Kluger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P. D'Angelo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas
Eve Maubec et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
Jean-Jacques Grob et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
Murtuza Bharmal et al.
FUTURE ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
Ulrike Leiter et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Association of steroid use with survival in solid tumours
Fausto Petrelli et al.
EUROPEAN JOURNAL OF CANCER (2020)
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma
Misha Amoils et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2019)
Neurofilament is superior to cytokeratin 20 in supporting cutaneous origin for neuroendocrine carcinoma
Lauren M. Stanoszek et al.
HISTOPATHOLOGY (2019)
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
Sandra P. D'Angelo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Basal Cell Carcinoma Review
Dennis P. Kim et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node positivity and association with overall survival
Rosalynn R. Z. Conic et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review
Michael R. Cook et al.
JAMA ONCOLOGY (2019)
Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women's Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma
Emily Stamell Ruiz et al.
JAMA DERMATOLOGY (2019)
Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness
Aaron M. Goodman et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
Noha Abdel-Wahab et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report
Michael A. Cardis et al.
BMC CANCER (2019)
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study
Thomas S. Uldrick et al.
JAMA ONCOLOGY (2019)
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
Jaclyn LoPiccolo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Todd C. Knepper et al.
CLINICAL CANCER RESEARCH (2019)
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
Biagio Ricciuti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
Vaia Florou et al.
Journal for ImmunoTherapy of Cancer (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma
Mahtab Samimi
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review
Noha Abdel-Wahab et al.
ANNALS OF INTERNAL MEDICINE (2018)
Emerging trends in the treatment of advanced basal cell carcinoma
Michael R. Migden et al.
CANCER TREATMENT REVIEWS (2018)
Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma
Howard L. Kaufman et al.
FUTURE ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics
Kelly G. Paulson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
John A. Thompson
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Merkel Cell Carcinoma, Version 1.2018 Clinical Practice Guidelines in Oncology
Christopher K. Bichakjian et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide
Kelly G. Paulson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma
Saranya Kodali et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2018)
Malignant adnexal tumors of the skin: a single institution experience
Tolutope Oyasiji et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2018)
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
Evidio Domingo-Musibay et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study
Jurgen C. Becker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
Paul W. Harms et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Nicolas A. Giraldo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma
Leandro J. C. Oliveira et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The role of neoantigen in immune checkpoint blockade therapy
Ming Yi et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)
Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival
Natalie Vandeven et al.
CLINICAL CANCER RESEARCH (2018)
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study
Kelly G. Paulson et al.
CANCER (2017)
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs
Dirk Schadendorf et al.
EUROPEAN JOURNAL OF CANCER (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Evan J. Lipson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab.
Kelly Garneski Paulson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Update on Merkel Cell Carcinoma
Paul W. Harms
CLINICS IN LABORATORY MEDICINE (2017)
Spectrum of Immune-Related Conditions Associated with Risk of Keratinocyte Cancers among Elderly Adults in the United States
Elizabeth L. Yanik et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)
Suzanne L. Topalian et al.
CANCER RESEARCH (2017)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding et al.
BLOOD (2017)
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
Gerald Goh et al.
ONCOTARGET (2016)
Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System
Kelly L. Harms et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Supportive care needs and distress in patients with non-melanoma skin cancer: Nothing to worry about?
Annett Koerner et al.
EUROPEAN JOURNAL OF ONCOLOGY NURSING (2016)
PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis
Nathaniel A. Slater et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2016)
Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base
Shailender Bhatia et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base
Shailender Bhatia et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
Jayasri G. Iyer et al.
CANCER MEDICINE (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy
Natalie A. Vandeven et al.
JOURNAL OF ONCOLOGY PRACTICE (2016)
The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma
Paul William Harms et al.
CANCER RESEARCH (2015)
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas
Stephen Q. Wong et al.
CANCER RESEARCH (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Large T and small T antigens of Merkel cell polyomavirus
Justin A. Wendzicki et al.
CURRENT OPINION IN VIROLOGY (2015)
Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012
Howard W. Rogers et al.
JAMA DERMATOLOGY (2015)
The relationship between UV exposure and incidence of skin cancer
Johan Moan et al.
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE (2015)
Managing Body Image Difficulties of Adult Cancer Patients
Michelle Cororve Fingeret et al.
CANCER (2014)
Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma
Curtis R. Pickering et al.
CLINICAL CANCER RESEARCH (2014)
Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma
Pritesh S. Karia et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma
Ahmed K. Alomari et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2014)
Mutational Landscape of Basal Cell Carcinomas by Whole-Exome Sequencing
Shyam S. Jayaraman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I
Aude G. Chapuis et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma
Kelly G. Paulson et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Real-world impact of education: treating patients with ipilimumab in a community practice setting
Blanca Ledezma et al.
CANCER MANAGEMENT AND RESEARCH (2014)
Chemotherapy Education for Patients With Cancer: A Literature Review
Ramsey B. Valenti
CLINICAL JOURNAL OF ONCOLOGY NURSING (2014)
Basal-Cell Carcinoma Incidence and Associated Risk Factors in US Women and Men
Shaowei Wu et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2013)
Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
Olga K. Afanasiev et al.
CLINICAL CANCER RESEARCH (2013)
Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008-A Swedish population-based study
Britta Krynitz et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Does Enrollment in Cancer Trials Improve Survival?
Christopher J. Chow et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2013)
HIV Infection Status, Immunodeficiency, and the Incidence of Non-Melanoma Skin Cancer
Michael J. Silverberg et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience
S. Yousuf Zafar et al.
ONCOLOGIST (2013)
Associations between cancer-related financial stress and strain and psychological well-being among individuals living with cancer
Linda Sharp et al.
PSYCHO-ONCOLOGY (2013)
Evaluation of AJCC Tumor Staging for Cutaneous Squamous Cell Carcinoma and a Proposed Alternative Tumor Staging System
Anokhi Jambusaria-Pahlajani et al.
JAMA DERMATOLOGY (2013)
PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
Evan J. Lipson et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Itch and Pain in Nonmelanoma Skin Cancer: Pain as an Important Feature of Cutaneous Squamous Cell Carcinoma
Kyle C. Mills et al.
ARCHIVES OF DERMATOLOGY (2012)
A systematic review of worldwide incidence of nonmelanoma skin cancer
A. Lomas et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study
Harri Sihto et al.
CLINICAL CANCER RESEARCH (2012)
Recurrence and Survival in Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma: Analysis of 153 Patients from a Single Institution
Ryan C. Fields et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Tumor Evasion from T Cell Surveillance
Katrin Toepfer et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival
Kelly G. Paulson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Histopathological Variants of Cutaneous Squamous Cell Carcinoma: A Review
Valerie R. Yanofsky et al.
JOURNAL OF SKIN CANCER (2011)
Antibodies to Merkel Cell Polyomavirus T Antigen Oncoproteins Reflect Tumor Burden in Merkel Cell Carcinoma Patients
Kelly G. Paulson et al.
CANCER RESEARCH (2010)
Cancer and Sexual Problems
Richard Sadovsky et al.
JOURNAL OF SEXUAL MEDICINE (2010)
Aggressive Behavior of Nonmelanotic Skin Cancers in Solid Organ Transplant Recipients
David G. Lott et al.
TRANSPLANTATION (2010)
Cellular Responses to Cisplatin-Induced DNA Damage
Alakananda Basu et al.
JOURNAL OF NUCLEIC ACIDS (2010)
Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma
V. Koljonen et al.
BRITISH JOURNAL OF CANCER (2009)
Tetrada of the possible mycophenolate mofetil embryopathy: A review
Paul Merlob et al.
REPRODUCTIVE TOXICOLOGY (2009)
Merkel Cell Carcinoma Histologic Features and Prognosis
Aleodor A. Andea et al.
CANCER (2008)
Clonal integration of a polyomavirus in human Merkel cell carcinoma
Huichen Feng et al.
SCIENCE (2008)
Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus
Jose Henrique Andrade Vila et al.
TRANSPLANTATION (2008)
Expression of p63 in cutaneous metastases
Jean Kanitakis et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2007)
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis
Andrew E. Grulich et al.
LANCET (2007)
Merkel cell carcinoma adjuvant therapy: Current data support radiation but not chemotherapy
Kelly M. Garneski et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Lymphatic mapping and sentinel node biopsy in Merkel's cell carcinoma
J. Ortin-Perez et al.
EJSO (2007)
Role of radiologic Imaging at the time of initial diagnosis of stage T1b-T3b melanoma
Molly Yancovitz et al.
CANCER (2007)
Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma - The Dana-Farber experience and meta-analysis of the literature
Sheela G. Gupta et al.
ARCHIVES OF DERMATOLOGY (2006)
Adjuvant local irradiation for Merkel cell carcinoma
Kevan G. Lewis et al.
ARCHIVES OF DERMATOLOGY (2006)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung
Mattheos Bobos et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2006)
Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers
B Llombart et al.
HISTOPATHOLOGY (2005)
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies
J Geisse et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Merkel cell carcinoma and HIV infection
EA Engels et al.
LANCET (2002)
The epidemiology of UV induced skin cancer
BK Armstrong et al.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY (2001)
Share Paper
